Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
01-07-2021
Genevant signs $600m liver fibrosis deal with Takeda
18-03-2021
Jonathan Weiss / Shutterstock.com
Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi (azilsartan).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Takeda, Edarbi, Arbor, EastPharma, Azurity, generic, NovaQuest
